期刊文献+

血清CA199、CA125和YKL40联合检测对卵巢癌的诊断价值 被引量:4

Serum CA199, CA125 and YKIA0 combined detecting for ovarian cancer diagnose value
下载PDF
导出
摘要 目的探讨血清CA199、CA125和YKL-40联合检测在卵巢癌诊断中的应用价值。方法分别用酶免分析法(EIA)和电化学发光法测定36例卵巢癌、38例卵巢良性肿瘤及40例健康对照妇女血清YKL-40和CA125、CA199水平,YKL-40以健康对照组95%可信区间的上限值为阳性,比较YKL-40和CA125、CA199在三组间、卵巢癌病人不同临床分期阳性率的差异。结果正常对照组血清YKL-40水平的95%可信区间的上限值为76.2ng/mL;卵巢癌患者血清YKL-60水平及阳性率显著高于卵巢良性肿瘤组和对照组(t=3.45,P〈0.01),而卵巢良性肿瘤组和对照组之间差异无统计学意义(t=1.62,P〉0.05)。Ⅲ/Ⅳ期卵巢癌患者血清YKL-40水平显著高于Ⅰ/Ⅱ期患者(t:2.81,P〈0.01)。CA125和CA199联检的阳性率为77.8%,YKL-40与CA125、CA199联合检测的阳性率可达到88.9%。结论YKL-40是一种新的诊断卵巢癌的肿瘤标志物,联合YKL-40,CA199、CA125三项检测可提高对早期卵巢癌诊断的灵敏度,对卵巢癌的诊断有重要临床价值。 Objective To study the application of combined detection of serum CA199, CA125, and YKL-40 to ovarian cancer diagno sis. Method Enzyme immtmoassay analysis (EIA) and were used to detect serum YKL - 40 and CA125, and CA199 values in 36 cases of ovarian cancer patients, 38 cases of benign ovarian tumor patients and 40 healthy women as the control group. In healthy group YKL-40 at 95% confidence interval upper limit is positive; and YKL-40 and CA125, CA199 values are compared among the three groups and in different clinical stages of ovarian cancer patients, their positive rates are also compared. Results The serum YKL - 40 at 95 % confidence interval upper limit is 71 .gng/mL; the serum YKL- 40 in ovarian cancer patients and its positive rate are significantly higher than the benign ovarian tumor group and the control group (t = 3.45, P 〈 0.01 ), and there is no significant difference between the benign ovarian tumors and the control group (t = 1.62,P 〉 0.05). Serum YKL-40 values in phase Ⅲ/Ⅳ ovarian cancer patients are significantly higher than that in phrase Ⅰ/Ⅱ patients(t = 2.81, P 〈 0.01 ). With combined detection of CA125 and CA199, the positive rate is 77.8 %, while with combined detection of YKL - 40 and CA125, CA199 the positive rate can reach 88.9 %. Conclusion YKL- 40 is a new tumor marker in ovarian cancer diagnosis, and combined detection of YKL- 40, CA199, CA125 can improve the sensitivity of early ovarian cancer diagnosis, so it has important clinical value in the ovarian cancer diagnosis.
出处 《医学检验与临床》 2012年第1期1-3,共3页 Medical Laboratory Science and Clinics
关键词 YKL-40 CA125 CA199 卵巢癌 肿瘤标志物 Ykl-40 CA125 CA199 Ovarian cancer Tumor markers
  • 相关文献

参考文献14

  • 1Ratto GB,CostaR,VassalloG. Twelveyearexperiencewithleftatrial resection in thetreatmentofnonsmall cell lung cance[J].nnThoracSurg,2004,(01):234-237.
  • 2李孟达,李志刚.血清CA125、CA199、CA153在卵巢浆、粘液性囊腺癌诊断和动态观察中的价值[J].癌症,1997,16(5):350-352. 被引量:35
  • 3陈蒲香,余秀兰.血清CA125、CA199检测在卵巢上皮性肿瘤中的临床意义[J].医学临床研究,2002,19(3):230-231. 被引量:16
  • 4Volck B,PriceP,Johansen JS. YKL40,amammalian memberof the chitinase family,is amatrix protein of specificgranules in human neu-trophils[J].Proc ssoc m Physicians,1998,(04):351-360.
  • 5RenkemaGH,BootRG,Muijsers O. Purification and characterization ofhuman chitotriosidase,anovelmemberof the chitnasefamily of pro-teins[J].Journal of Biological Chemistry,1995,(05):2198-2202.
  • 6DehnH,HogdallEV,Johansen JS. PlasmaYKL40,as prognostictumormarkerinrecurrentovariancancer[J].ctaOstetGynecolScand,2003,(03):287-293.
  • 7Dupont J,Tanwar MK,Thaler HT. Early detection and prognosis of ovarian cancer using serum YKL-40[J].Journal of Clinical Oncology,2004,(16):3330-3339.
  • 8孔宪涛.肿瘤特异抗原和相关抗原的研究现状及检测[J].中华检验医学杂志,2000,23(1):56-58. 被引量:140
  • 9连利娟;林巧稚.妇科肿瘤学[M]北京:人民卫生出版社,2006410-413459-460.
  • 10Fioretti P,Gaddueei A,Ferdeghini M. The concomitant determin-stion of different serum tumor markers in epit helial ovanian cnacer:relevancefor monitoring the response to chemotherapy and follow up of pa-tients[J].Gynecologic Oncology,1992,(02):155.

二级参考文献7

共引文献198

同被引文献39

  • 1陈荣策,石胜,黄伟刚.免疫发光法检测CA199在胰腺疾病诊断中的临床意义[J].海南医学,2004,15(9):122-122. 被引量:3
  • 2王凤君,黄文华,黎鳌.触珠蛋白研究进展[J].生物化学与生物物理进展,1994,21(5):386-389. 被引量:5
  • 3谭丽娜,黄进华.结合珠蛋白的研究进展[J].国际病理科学与临床杂志,2006,26(1):43-47. 被引量:39
  • 4萨姆布鲁克J 拉塞尔DW.黄培堂 王嘉玺 朱厚础 等译.分子克隆实验指南[M]第3版[M].北京:科学出版社,2002.8..
  • 5陈瑁.2型糖尿病糖脂代谢与血清CAl99的相关性研究.中国健康月刊,2011,30(11):43-44.
  • 6李会英.酶联免疫吸附试验影响因素的分析[J].检验医学与临床,2007,4(10):985-986. 被引量:23
  • 7Miriam Lenhardl, Alexandra Tsvilina, Lan Schumacher, et al. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer[J]. BMC Cancer, BMC Cancer, 2013,12(1): 2.
  • 8Dominic Varga, Miriam Deniz, Lukas Schwentner, et al.Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects [J]. International Journal of Molecular Sciences, 2013,14( 1 ): 640-673.
  • 9Ye B, Cranmer DW, Skates S J, et al. Haptoglobin-alpha unit as poten- tial serum biomarker in ovarian cancer: identification and Charteris- zation using teleonomic profession and mass spectrometry [J]. Clinic Cancer Res, 2003, 9:2904-2911.
  • 10M D Parra, P Fuentes, F Tecles, et al. Porcine Acute Phase Protein Concentrations in Different Diseases in Field Conditions[J]. Journal of Veterinary Medicine, 2006, 53(10): 488-493.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部